These results clearly demonstrated that MGAT2 inhibition improved dyslipidemia, obesity, and diabetes, suggesting that compA is an effective therapeutic for obesity-related metabolic disorders. Here, MGAT2 is linked to obesity due to melanocortin 4 receptor deficiency.